How to Join This Clinical Trial - NCTNCT03983954

Learn how to participate in this PHASE1 trial studying an investigational therapy for ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma, Endometrial Cancer, Renal Cell Carcinoma, Urothelial Cancer, Head and Neck Squamous Cell Carcinoma, Mesothelioma, Melanoma, Hepatocellular Carcinoma, Prostate Cancer, NSCLC, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Colorectal Cancer Metastatic, GastroEsophageal Cancer, NSCL2 Gene Mutation, Esophageal Cancer. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma, Endometrial Cancer, Renal Cell Carcinoma, Urothelial Cancer, Head and Neck Squamous Cell Carcinoma, Mesothelioma, Melanoma, Hepatocellular Carcinoma, Prostate Cancer, NSCLC, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Colorectal Cancer Metastatic, GastroEsophageal Cancer, NSCL2 Gene Mutation, Esophageal Cancer. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied

ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma, Endometrial Cancer, Renal Cell Carcinoma, Urothelial Cancer, Head and Neck Squamous Cell Carcinoma, Mesothelioma, Melanoma, Hepatocellular Carcinoma, Prostate Cancer, NSCLC, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Colorectal Cancer Metastatic, GastroEsophageal Cancer, NSCL2 Gene Mutation, Esophageal Cancer

Treatment Being Tested

Investigational treatment

Study Phase

PHASE1 - Early safety study

Enrollment Status

ACTIVE_NOT_RECRUITING

Study Identifier

NCTNCT03983954 - ClinicalTrials.gov Identifier

Sponsored By

Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

• Initial screening to determine eligibility
• Regular study visits and health assessments
• Receiving the study treatment or placebo
• Medical monitoring and follow-up care
• Contributing to medical research that may help others
• Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

• Close medical monitoring by healthcare professionals
• Access to potential new treatments
• Compensation for time and travel (varies by study)
• No-cost study-related medical care
• The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 9 locations. Find a study site near you:

How to Enroll in This Study

To learn more about participating in this PHASE1 clinical trial for ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma, Endometrial Cancer, Renal Cell Carcinoma, Urothelial Cancer, Head and Neck Squamous Cell Carcinoma, Mesothelioma, Melanoma, Hepatocellular Carcinoma, Prostate Cancer, NSCLC, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Colorectal Cancer Metastatic, GastroEsophageal Cancer, NSCL2 Gene Mutation, Esophageal Cancer:

1. Review the eligibility criteria with your healthcare provider
2. Contact the study team for a pre-screening interview
3. Schedule an in-person screening visit if eligible
4. Review and sign the informed consent form
5. Begin participation in the clinical trial

Why Choose Quri.ai as Your Clinical Trial Matching Service

Quri.ai is a free clinical trial matching service that helps patients connect with research sites. We make it easier to:

• Find clinical trials that match your condition
• Get matched to the right study location near you
• Connect directly with study coordinators
• Understand if you qualify with simplified eligibility screening
• Navigate the enrollment process with personalized support
• Access new treatments through clinical research participation